Skip to main content
All lobbying filings

ALKERMES, INC.

Lobbying for ALKERMES, INC.

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2025 · Massachusetts · House · Senate · $830,000.00 expenses · posted Jul 18, 2025

Official filing document

 Bills named in this filing 6
 Lobbying activity 4
Tariff (miscellaneous tariff bills)

Policies impacting pharmaceutical distribution

Medicare/Medicaid

Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;

Health Issues

Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act

Alcohol and Drug Abuse

Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem